Boston Scientific news from FiercePharma
NewsBoston Sci recalls 2,200 stents
Boston Scientific has recalled more than 2,200 stents because the tip of the device used to implant them can break off during surgery, causing stroke or internal injury. The artery-opening Read more...
Boston Scientific's stent data flawed
Boston Scientific's new heart stent, awaiting approval for U.S. sales, is backed by flawed research despite the company's claims of success in a clinical trial, according to a Wall Street Journal Read more...
Cleveland Clinic shuns Boston Scientific stents
Back in 2006, Cleveland Clinic anointed Boston Scientific as its preferred supplier of drug-coated stents. At the time, though, Johnson & Johnson had the only other coated stent on the U.S. Read more...
Justice probes biliary stent marketing
The U.S. Department of Justice has launched a probe of the bile-duct stent market, trying to determine whether companies such as Abbott Laboratories, Boston Scientific and Johnson & Johnson Read more...
Earnings up, earnings down for drugmakers
A plethora of drug-and-device results today, from falling profits at Boston Scientific and Schering-Plough to higher earnings and flat sales at Merck. Here's the roundup:
Merck posted net income of Read more...
Boston Sci CEO plans to stick around
Tobin, Tobin, he's our man. Or so says Boston Scientific. The device maker says chief executive Jim Tobin will be "extending his tenure," planning to stay with the company "for the foreseeable Read more...
ALSO NOTED: Abbott's Xience shows well against Boston Sci stent;AstraZeneca nabs new indication for Seroquel
> Abbott Laboratories' waiting-in-the-U.S.-wings stent, Xience, is as safe as and perhaps more effective than the current market leader made by Boston Scientific, according to new data presented Read more...
ALSO NOTED: Pfizer demands peer reviews from NEJM; Novartis gets EU nod for diabetes combo;
> Pfizer wants the New England Journal of Medicine to turn over confidential peer reviews of studies involving the painkillers Celebrex and Bextra; those articles have been cited in plaintiffs' Read more...
SPOTLIGHT: Inventor wins $431M from Boston Sci
A Texas jury ruled that Boston Scientific's drug-coated stents violate a 1997 patent and awarded $431 million to patent holder Dr. Bruce N. Saffran. Confident it can win on appeal, the company won't Read more...
ALSO NOTED: Boston Sci reports $495 million loss; FDA on the fence about Requip XL;
> Boston Scientific reported a $495 million loss for 2007, on a 6.9 percent increase in revenues to $8.357 billion; drug-coated stent sales worldwide dropped to $1.788 billion from $2.358 billion, Read more...
| Press ReleasesPRESS RELEASE: Boston Scientific Announces Amended Agreement to Settle Product Lawsuits Boston Scientific Announces Amended Agreement to Settle Product Lawsuits NATICK, Mass., Nov. 19 -- Boston Scientific Corporation today announced that an amended agreement has been reached to settle Read more... PRESS RELEASE: Boston Scientific Announces New Initiatives to Increase Shareholder Value Boston Scientific Announces New Initiatives to Increase Shareholder Value Approximately 2,300 positions to be eliminated worldwide NATICK, Mass., Oct. 17 -- Boston Scientific Corporation today Read more... |
Get more Boston Scientific coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets